Physician profile
Rachel Monderer
NPI 1568467728
$3,858.78
in general payments reported to CMS, 2019-2025
32 companies · $940 in 2025
The $940 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $84.89 · 2021: $219 · 2022: $659 · 2023: $745 · 2024: $965 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.77 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.10 | 2019-2025 | |
| Pfizer INC. | $506.66 | 2019-2025 | |
| Novo Nordisk INC | $466.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $402.33 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $400.81 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $183.48 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $169.79 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $125.56 | 2022-2025 | |
| Esperion Therapeutics, INC. | $111.30 | 2022-2023 | Nexletol |
| Amgen INC. | $94.73 | 2019-2025 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $94.44 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.36 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $76.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $72.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $44.25 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $33.88 | 2024 | Zio Monitor, Zio Xt Patch |
| Phathom Pharmaceuticals, INC. | $30.33 | 2024-2025 | Voquezna |
| Abbott Laboratories | $24.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.08 | 2023 | Gvoke Hypopen |
| Tactile Systems Technology INC | $23.47 | 2023 | Entre Plus, Flexitouch Plus |
| Lundbeck LLC | $23.31 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $21.75 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $20.09 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2022 | |
| Philips North America LLC | $18.23 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2019 | |
| Merck Sharp & Dohme LLC | $17.96 | 2023 | Steglatro, Belsomra |
| Corcept Therapeutics | $15.70 | 2025 | Korlym |
| Dynavax Technologies Corporation | $15.31 | 2024 | Heplisav-B |
| Corium, LLC | $14.96 | 2023 | Adlarity |
| Inogen, INC. | $12.99 | 2022 | |
| Seqirus USA INC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Monderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.